Related Experiment Video
Updated: Apr 17, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Is lithium a neuroprotective agent?
Thuy M Vo1, Paul Perry, Michael Ellerby
1Touro University California College of Pharmacy, Vallejo, California, USA.
Background:
Lithium was the first clinically effective mood stabilizer marketed worldwide. However, the medical literature suggests that lithium may have an indication as a neuroprotective agent.
Methods:
This review discusses the pharmacologic activity and potential effectiveness of lithium in the context of Alzheimer disease (AD) and Parkinson's disease (PD), the 2 most prominent neurodegenerative disorders in the United States. The toxicities of lithium, including lithium-induced extrapyramidal symptoms (LI-EPS) and cognitive impairments at therapeutic blood levels, are discussed. Cases that are thought to illustrate LI-EPS and cognitive impairments are critiqued.
Results:
Animal studies have shown positive results regarding the neuroprotective and antioxidant properties of lithium. Human studies indicate a potential benefit of lithium for improving cognition. Ongoing replicative studies are attempting to confirm the effectiveness and efficacy of lithium for treating patients diagnosed with AD or PD.
Conclusions:
The available medical literature supports the conclusion that lithium should be considered as a research candidate medication for the treatment of neurologic diseases of dementias and PD.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Long-term Potentiation
Long-term Potentiation
Hebbian LTP
LTP can occur when...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Ligand-Gated Ion Channel Receptor: Gating Mechanism

